Prevalence of Hepatitis B in HIV infected persons: choice of antiretroviral therapy regimen and implications for screening by Reidy, Derval
Prevalence of Hepatitis B in HIV infected 
persons: Choice of antiretroviral therapy 
regimen and implications for screening . 
• 
Candidate: 
Student Number: 
Supervisor: 
Submitted: 
Derval Reidy 
RDYDER002 
David Coetzee 
31 October 2014 
A mini-dissertation submitted to the Faculty of Health Sciences, University of Cape Town, in 
partial fulfilment of the requirements for the degree of Master of Public Health (General) 
Cape Town, 2014 
1 
Un
ive
ris
ty 
of 
Ca
pe
 To
wn
 
  
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
DECLARATION 
MPH (General} Mini-Dissertation 
I, Derval Reidy Student No. RDYDER002 hereby declare that the work on 
which this dissertation/thesis is based is my original work (except where 
acknowledgements indicate othervvise) and that neither the whole work nor any part of it 
has been, is being, or is to be submitted for another degree in this or any other university. 
I empower the university to reproduce for the purpose of research either the whole or any 
portion of the contents in any manner whatsoever, 
Signature: 
2 
Signature Removed
Abstract 
Background: Limited data and few studies have shown the prevalence of Hepatitis B in the 
HIV infected population in South Africa, whether these patients are on appropriate 
antiretroviral therapy and the effect of Hepatitis B on liver function in co-infected persons. 
Objectives: The objectives of this study were to determine the prevalence of Hepatitis B 
surface antigemia (HBsAg) in healthy HIV positive persons screened for a vaccine trial and 
the proportion of those eligible for antiretroviral therapy that were receiving optimal anti-
viral treatment, namely tenofovir and/or lamivudine. The relationship between Hepatitis B 
carriage and liver function was also determined in co-infected persons as measured by liver 
function tests. 
Methods: A cross sectional study was conducted from 30th August 2011 to 24th April2013 to 
determine the prevalence of HIV /HBV co-infection in persons attending a clinical trial site in 
an urban clinical trials unit of Cape Town. Participants self-presented to the clinic and once 
consented were enrolled into the study and provided blood for HIV confirmatory test, 
Hepatitis B sAg, CD4, VL, full blood count, liver function and renal function tests. 
Results: 638 participants were enrolled into this cross sectional study. 24 (3.8%) were 
Hepatitis B sAg positive, which was lower than expected. Ofthe 24 HIV/HBV co-infected 
participants, 19 (79 .2%) were on antiretroviral therapy, 14 (73. 7%) of these were on a 
tenofovir/lamivudine regimen the remaining 5 (26.3%) were not on a tenofovir regimen. Five 
of the co-infected participants were not on ARVs because their CD4 count was above the 
recommended South African guidelines for treatment i.e. greater than 350 1 QA6/l. Male 
participants were three times more likely to be HBsAg positive. Elevated Alanine 
aminotransferase (ALT) and Aspartate Aminotransferase (AST) were associated with HBsAg 
seropositivity. 
Conclusion: This study showed a lower HIV /HBV co-infection prevalence rate than reported 
from other locations in South Africa suggesting geographical variability. Appropriate 
guidelines are required to ensure that co-infected patients are identified and treated with the 
most appropriate anti-retroviral regimens. Screening for HBV is also recommended in HIV-
infected cohorts. 
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1. PROTOCOL SUMMARY: 
Title Prevalence of Hepatitis Bin HIV infected persons: Choice of antiretroviral 
therapy regimen and implications for screening. 
Study design Observational cross sectional study 
Population All HIV positive participants recruited for a TB vaccine study attending a clinic 
in Khayeltisha, Cape Town. 
Site Khayelitsha, Cape Town. 
Study The study objectives will be to ascertain: 
objectives 
1. The prevalence of Hepatitis B surface antigemia in HIV positive persons 
screened for a vaccine trial. 
2. The percentage of those eligible for ART that are receiving optimal anti-
viral treatment such as tenofovir and/or lamivudine. 
3. The relationship between Hepatitis B carriage and liver abnormalities 
determined by Liver Function Tests in co-infected persons. 
Methods A sample of 638 HIV positive participants recruited for a TB vaccine study from 
30th August 2011 to 24th April2013. 
All participants had their HIV status confirmed and bloods taken for hepatitis B 
surface antigen, liver function, viral loads and CD4 tests as part of the vaccine 
trial. 
The ART status of every participant was also ascertained. 
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2. Background Information and Rationale 
HIV and Hepatitis B (HBV) represent two significant global health problems. Both are 
preventable viral infections which are on the increase. Currently there are an estimated 50 
million people living with HIV [1] and 400 million people living with Hepatitis B [2]. An 
estimated 1.2 million people die annually from complications associated with chronic 
Hepatitis B [3]. Chronic HBV is endemic in Sub-Saharan Africa with prevalence rates 
varying from 0.3 to 15% [4]. HIV rates in Sub-Saharan Africa are estimated to be 4.9% 
amongst 15-49 year olds in 2011 [ 5]. In 2011, HIV prevalence rates in South Africa were 
over 1 0% [ 6]. Many of the countries where Hepatitis B is endemic also have a high burden 
ofHIV leading to an increase in HIV/HBV co-infection rates [2]. Co-infection leads to 
increased liver morbidity and mortality, increased hepatitis B viral replication and 
hepatotoxicity induced by the combination ofHBV and anti-retroviral medication [2]. Also, 
there is evidence to suggest that HIV accelerates the progression ofHBV liver disease [7]. 
Globally there is very little data on HIV /HBV co-infection rates, particularly in countries 
with high prevalence of chronic Hepatitis B. Estimated co-infection rates in Sub-Saharan 
Africa are 15% but vary greatly depending on the country [7]. Co-infection prevalence rates 
in South Africa are currently unknown. Different studies conducted in urban clinics in 
Johannesburg have estimated a 5% HBsAg positivity rates in HIV positive patients [8] and up 
to 17% in an industrial clinic setting [9]. 
There is an increased need to screen for HBV prior to commencement of anti-retroviral 
(ARV) therapy and to screen patients currently on ARV s to ensure they are receiving optimal 
treatment as some antiretrovirals are also effective against HBV. There is an obligation to 
increase community and health care professional awareness surrounding co-infection to 
prevent further spread of the virus and to ensure optimal care. The anti-retroviral treatment 
10 
programme has reversed the decline in life expectancy and it has increased from 48 years pre-
ARVs to 54.9 years in 2011 in South Africa [6]. As the HIV and Hepatitis B epidemics 
progress we need to understand the impact ofHBV on liver function in co-infected persons. 
The aim ofthis study is to determine the HIV/HBV co-infection rate amongst HIV-infected 
participants of a TB vaccine trial and to determine if these co-infected participants are 
receiving optimal anti-retroviral therapy. 
3. Literature Review 
The modes of transmission for both these viral infections are contact with blood or other 
body fluids of an infected person i.e. through unprotected sexual contact, perinatally from 
mother to child, or via infected blood in needle stick injuries or use of infected needles by 
injecting drug users. However, Hepatitis B is 50 to 100 times more infectious than HIV [1 0]. 
Hepatitis B can be a serious viral infection which affects the liver. The presence of HBsAg 
for a minimum of six months indicates chronic infection. Ma [ 11] estimates that HBV is the 
fourth most common cause of cancer death amongst Asian Americans. Approximately 20% of 
liver cirrhosis amongst black Africans is secondary to HBV [12]. 
Patterns of transmission differ between developed and developing countries. In developed 
countries acquisition of Hepatitis B mainly occurs in adulthood in high risk groups through 
intravenous drug use or sexual exposure. In contrast, acquisition of Hepatitis B in developing 
countries is predominantly perinatal (from mother to infant at birth) or horizontal (i.e. that 
occurring without apparent parenteral, sexual or perinatal exposure)[13]. The predominant 
mode ofHBV transmission in the world is perinatal [1]. A pregnant woman who is Hepatitis 
Be antigen positive has a 90% probability of transmitting HBV to her new born child. 
Twenty five percent of these children will die in adulthood from chronic liver disease or liver 
cancer [ 1]. Little is known about HBV prevalence in the general population in South Africa. 
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Chronic HBV is the cause of 1.2 million deaths per year worldwide [3]. Sub-Saharan Africa 
has the second highest HBV prevalence rates following Asia [14]. However, only a small 
proportion of patients with chronic HBV are placed on appropriate antiviral treatment 
resulting in an increased risk of liver cancer [3]. 
The patterns of transmission for HIV acquisition also differ between developed and 
developing countries. In developed countries HIV incidence is mainly in high risk adult 
groups - men who have sex with men, sex workers and intravenous drug users. However, 
sexual acquisition is increasing in heterosexual groups. In developing countries and in 
particular sub-Saharan Africa, HIV is predominantly perinatal or horizontal transmission 
[13]. The majority of the data regarding co-infection comes from developed countries and do 
not reflect transmission patterns in developing countries. 
HIV is a retrovirus which attacks the immune system, causing AIDS (Acquired Immune 
Deficiency Syndrome) if untreated. Although not curable, HIV infection can be well 
controlled by anti-retroviral medications. Since the introduction of anti-retrovirals in South 
Africa, there has been a marked decrease in HIV related deaths. 
The South African Clinicians Society [13] has warned that HIV-Hepatitis B co-infected 
patients are at increased risk of morbidity and mortality. The World Health Organization's 
clinical protocol for Management ofHBV and HIV co-infection highlights that patients 
receiving anti-retroviral treatment have an increased risk of hepatotoxicity and that 
interruption in treatment can cause hepatic flare ups. HIV has a significant impact on HBV, it 
increases the risk of liver cirrhosis and end stage liver disease in co-infected individuals. The 
risk ofliver related mortality is 2-3 times higher in co-infected individuals compared to 
mono-infected patients [ 14] [ 15]. Also, HIV co-infection is associated with more frequent 
flares of hepatic transaminases. Immune reconstitution inflammatory syndrome (IRIS) can 
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occur once a patient starts on Antiretrovirals (ART). Interruption of HIV /HBV treatment can 
result in hepatic flare ups and or the development of resistance to treatment [ 16]. 
Both the World Health Organization and the South African HIV Clinician's society 
recommend early screening for Hepatitis Bin HIV infected patients. This should be 
conducted at the time of diagnosis. Despite these recommendations, the National Department 
of Health guidelines no longer recommend Hepatitis B testing in HIV infected adults. 
Hepatitis B screening (HBsAg) is advised in the 201 0 guidelines in patients starting 
nevirapine but only in patients with a raised ALT. Prior to that screening for HBsAg was not 
included in the guidelines. 
The ARV s lamivudine and tenofovir are part of the effective treatment of both HIV and HBV 
and both are available in South Africa. Tenofovir was approved for the treatment of HBV in 
2008 [7] and became available in South Africa in 2010. Lamivudine has a poor resistance 
profile and drug resistance mutations commonly occur after two to three years ofuse [18]. In 
addition HBV flare-ups often occur if HBV treatment is stopped [19]. Tenofovir has a much 
better resistance profile and fewer side effects than lamivudine and is now part of first line 
therapy for HIV. Because tenofovir is part of the first line regimen for HIV and is the 
preferred treatment option for both HIV and HBV, it was argued that HBV screening was no 
longer required. 
HBV vaccination has been routinely available as part of the Expanded Programme on 
Immunization (EPI) in South Africa since 1995 [12]. However, persons born before 1995 are 
susceptible to HBV. All HIV-infected persons born prior to this year should therefore be 
screened for HBV and vaccination should be provided if not infected or ifthey missed part of 
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their vaccination doses. In persons who are not co-infected with HIV, tenofovir may provide 
pre-exposure prophylaxis against HBV [20]. 
There is an urgent need to determine the prevalence of HBV infection in HIV-infected 
persons, the proportion ofHIV/HBV co-infected persons on appropriate ARVs, the effect of 
HBV on the liver in co-infected persons and early detection of liver complications. This study 
will address these key issues. 
4. Study Aims and Objectives 
4.1 Research Questions 
What is the prevalence of HBV surface antigemia in a healthy HIV infected 
adult cohort of participants screened for a Tuberculosis vaccine trial? What 
percentage ofthese participants are on appropriate anti-retroviral treatments? 
Do co-infected participants with HIV /HBV have abnormal liver function tests? 
4.2 Study Aims 
This study aims to determine the Hepatitis B prevalence rates in a healthy HIV 
infected adult cohort of participants screened for a Tuberculosis vaccine trial 
and ifthese participants are on appropriate anti-retroviral treatment. 
4.3 Objectives 
The study objectives will be to ascertain: 
4.3.1 What is the prevalence of Hepatitis B surface antigemia in HIV positive 
persons screened for a TB vaccine trial? 
4.3.2 What percentage of those co-infected participants are receiving 
appropriate optimal therapy such as tenofovir/lamivudine or emtricabine? 
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5. Methods 
4.3.3 What is the relationship between Hepatitis B co-infection and 
abnormality in Liver Function Tests? 
5.1 Study design and setting 
This will be an observational cross sectional study using data from a pre-existing TB 
vaccine trial. All HIV-infected participants aged 18-50 years of age screened for the 
TB vaccine trial at a clinical trials unit in Khayelitsha from 30 August 2011 to 24 
April2013 will be included in this cohort. Khayelitsha is an urban township on the 
outskirts of Cape Town. Adults aged 15-54 years of age comprise 66.7 % of the 
population. Half of all adults are unemployed and of those employed, 80% earn less 
than R1600 per month [18]. 
5.2 Study Population 
The study population will include all HIV positive participants screened for a TB 
vaccine trial and identified as HIV-infected as part of the screening process for the 
vaccine trial. 
5.2.1 Eligibility criteria 
The following participants will be included in this cohort: 
Inclusion Criteria: 
• Confirmed HIV ELISA positive 
• Aged 18-50 years on day of screening 
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Exclusion Criteria: 
• HIV negative. 
• No blood results available. 
For full inclusion and exclusion criteria for the TB vaccine trial refer to Appendix 1. 
5.2.2 Method of sampling 
All HIV infected participants enrolled in the TB vaccine trial over a twenty month 
period from 30 Aug 2011 to 24 April2013 will be included. In order to determine the 
proportion of co-infected participants on the appropriate ARV s a sub-sample will 
include all co-infected (HIV/HBV) participants ofthe TB vaccine trial. 
5.2.3 Sample size 
If the expected prevalence of co-infection is 4%, a sample of 638 HIV-infected 
participants will provide an estimate with a 1.25% margin of error. Calculating the 
confidence interval for a proportion, the margin of error will be 1.25%. In the sub-
sample of co-infected patients a sample size of 638 will have a 95% confidence 
interval of2.75 to 5.25% 
5.3 Study Procedures 
All HIV-infected participants screened for the TB vaccine trial will be eligible for this 
study. Participants with confirmed HIV laboratory results will be entered into the 
study. Information will be retrieved from information gathered from the TB vaccine 
trial. This study will not require any additional laboratory tests or procedures or study 
visits. 
5.4 Study endpoints 
• Prevalence rate of co-infected HIV /HBV participants. 
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• Proportion of co-infected participants on appropriate ARVs 
• Proportion of co-infected participants with abnormal liver function 
tests. 
5.5 Feasibility 
This study will use data from the TB vaccine trial conducted in Khayelitsha. No new 
data will be collected. No additional staff will be required for this study. 
6. Measurement and Field Management 
6.1 Instruments 
All data will be obtained from the TB vaccine study. Basic demographic details, 
contact information and date of first screening visit will be collected from the clinic 
folder and completed on a study log sheet. 
Information will be retrieved from the TB study data base - age, ARV status, if on 
ARV which ARV s, consumption of alcohol, smoking status, laboratory results -
confirmation ofHIV and HBV status, CD4, viral load, liver function tests. 
Regarding alcohol consumption, the following questions will be asked to ascertain the 
amount of alcohol participants consumed (A unit is defined as 1 drink= half large 
beer, glass ofwine, shot of spirit)) 
Regarding alcohol consumption, are you a Non-drinker; Currently consume alcohol; 
Ex-drinker> 1 year or an Ex-drinker< 1 year. 
If current drinker, how many drinks have you consumed in the last week? 
0 units; 1-7 units or > 7 units 
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6.2 Variables 
The dependent variable will be HIV/HBV positive. Independent variables will include 
age at time of screening, sex, ARV status, consumption of alcohol, smoking status and 
laboratory results. 
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6.2.1 Table 1. Variables Table 
Variable Scale Options 
Dependent variable: 
HIV ELISA confirmation Binary Yes=1 
No=O 
Hepatitis B s Antigen Binary Yes=1 
confirmation 
No=O 
Independent variables: 
Age of participant Continuous 18-50 years 
Sex Binary Male=1 
Female=O 
ARV status Binary Yes=1 
No=O 
Types of ARV s Nominal Tenofovir/lamivudine, 
emtricabine/non-nucleoside 
reverse transcriptase inhibitor. 
Alcohol consumption Binary Yes=1 
No=O 
Laboratory Results: 
CD4 Continuous Range: 500- 2010X 10/\6/1 
HIV Viral Load Continuous Range: <50-500,000 copies/ml 
Bilirubin Continuous Range: 0-21 ~-tmol/1 
Alanine Transferase Continuous Range: 5-40 U/L 
Aspartate Transaminase Continuous Range: 5-40 U/L 
Alkaline Phosphatase Continuous Range: 40-120 U/L 
GammaGT Continuous Range: 0-35 U/L 
19 
6.3 Validity and reliability 
Quality control measures will be taken to ensure that all study procedures were 
retrieved according to the protocol. Data capturing sheets will be marked with 
participant specific study numbers and stored to ensure easy retrieval in the case of 
queries. All data is checked against source documentation to ensure that the correct 
information has been entered. 
For this study all data will be checked through a computer based listings of variables 
to assess for any inconsistencies or missing values in the dataset. Categorical data will 
be checked for correct coding and missing variables. Numerical variables will be 
checked for plausible ranges and missing values. Where "stem and branch" questions 
are used, they will be cross-checked for any inconsistencies by comparing the answers 
to each of those questions. Any inconsistencies and or missing values identified will 
be queried and tracked back to the source documents to help investigate and resolve 
the problem using the study number. 
7. Statistical and Data Management and Analysis 
7.1 Data management and Statistical analysis 
Numerical data will be summarised using means and standard deviations or medians 
and interquartile ranges for the overall cohort depending on the distribution of data. 
For binary outcomes, proportions with 95% confidence intervals will be presented. 
Chi-squared and Fisher's Exact tests will be used in univariate analysis. Odds ratios 
will be calculated and reported with 95% confidence intervals. 
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A multivariate logistic regression model will explore associations between 
independent risk factors (age, gender, smoking status, alcohol consumption, ARV 
status) and the dependent variable, positive HIV and HBV status. Further variables 
are described in the Table 1 Variables Table. Analysis will also be conducted to assess 
and adjust for possible confounding by variables such as age and gender. All data will 
be analysed using Stata version 12. 
8. Ethics 
Full ethics approval has been obtained for the vaccine trial "A Phase 2, Proof of concept, 
Randomized, Double-blind, Placebo-controlled Study to evaluate the Protective efficacy 
against TB disease, safety and immunogenicity ofMVA85A/AERAS-485 in Healthy, HIV-
infectedAdults", ethics refOOl/2010 (Appendix 1). 
All information which will be used for this study has been approved as part of the above TB 
vaccine study. All participants have signed full informed consent to be part of the TB vaccine 
trial and this study will not require any additional information from the participants. 
Written informed consent was obtained from all participants within the confines of the TB 
vaccine trial. Full informed consent has been obtained in the preferred language of the 
participant which will be Xhosa or English which are the main languages spoken locally. 
Participation is voluntary and participants may withdraw from the study at any time if they 
choose to without having to give a reason. 
The study is conducted according to the principles of Good Clinical Practice and followed 
ICH-GCP and SA GCP guidelines. 
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9. Stakeholders and Reporting 
The results of this study will be disseminated to all relevant stakeholders including the 
Western Cape Provincial Health Department, City of Cape Town Health and staffworking at 
clinic where the trial was conducted. In addition feedback will be given to local community 
representatives. The study findings will be submitted for publication to a peer-reviewed 
journal of public health (South African Medical journal) within a year of study completion. In 
addition the findings may be presented at both a national and international conference. 
10. Strengths and Limitations 
The major strengths ofthis study are that it will ascertain HIV/HBV co-infection rates within 
this population. This study will provide critical information on current prevalence rates, if 
participants are on appropriate ARV s given their Hepatitis B status and if co-infected 
participants have abnormal liver function tests. 
11. Logistics 
11.1 Budget 
No additional budget is required for this study and any expenses incurred will be covered by 
the vaccine trial. 
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11.2 Timeline for study completion 
Year 2013 
Month A S 0 N D 
Ethics Submission 
Database - develop 
Data collection 
Data entry 
Data analysis 
Dissemination 
Write-up and publish 
23 
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1. Abbreviations and acronyms 
AIDS 
ALT 
ART 
AST 
CD4 
EPI 
HBV 
HBeAg 
HBsAg 
HIV 
WHO 
Acquired Immune Deficiency Virus 
Alanine aminotransferase 
Anti-Retroviral 
Aspartate aminotransferase 
CD4+ lymphocytes 
Expanded Program on Immunization 
Hepatitis B Virus 
Hepatitis B e Antigen 
Hepatitis B s Antigen 
Human Immunodeficiency Virus 
World Health Organization 
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2. Introduction and Objective of Literature Review 
This literature review focuses on Human Immunodeficiency Virus (HIV) and Hepatitis B 
(HBV) co-infection including the global epidemiology of these diseases, the epidemiology in 
sub-Saharan African and more specifically in South Africa. Particular attention is also paid to 
the clinical diagnosis, aetiology and prognosis of co-infection. A review of the global 
guidelines for the treatment of co-infection from the World Health Organization and from the 
South African Clinician's Society is included. A review of studies based in South Africa on 
co-infection is also conducted. 
The objectives of this literature review are: 
• To describe studies on the prevalence ofHIV, Hepatitis Band co-infection rates, 
globally and in South Africa. 
• To describe guidelines for co-infected patients in terms of anti-retroviral (ARV) 
treatment as well as studies of current practices. 
• To describe studies of liver function of co-infected patients. 
3. Search Strategy 
The following strategy was used to inform this literature review: 
Strategy: Search engines were used to search for combinations of the listed search 
items as stated below. Relevant articles suggested by search engines were included. 
References in articles were checked so as to identify any other relevant studies. 
Quantitative studies were included. Articles describing systematic review, case 
reports, observational studies, case series and trials were included. The initial search 
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strategy focused on co-infection from Sub-Saharan Africa but due to the limited 
nature of research from Africa, research from the developed world was also included. 
World Health Organization treatment guidelines, South African Clinician's society 
treatment guidelines, WHO reports, UNAIDS reports were sourced from their 
websites for information regarding current prevalence rates and standard of care. 
Search Terms: 
HIV and Hepatitis B co-infection 
HIV in Sub-Saharan Africa/South Africa 
Hepatitis B in Sub-Saharan Africa/South Africa 
HIV and Hepatitis B co-infection in Sub-Saharan Africa/South Africa 
Recommended ART treatment in co-infected HIV and Hepatitis B 
HIV and Hepatitis B and abnormal liver function as determined by liver function 
tests. 
Search Engines: Pubmed, Google, Google Scholar, Science Direct, Medline. 
4. Summary of Literature Review 
4.1 HIV 
Currently there are an estimated 50 million people living with HIV[1]. The African 
continent carries the bulk of infection and HIV prevalence in sub-Saharan Africa in 
2011 was estimated to be 4.9% amongst 15-49 year olds [2]. 
South Africa has one of the highest rates of HIV infection in the world. In 2011, 
10.6% ofthe population were infected with HIV and 16.6% ofthe adult population 
aged 15-49 were HIV positive [3]. 
HIV is a retrovirus which attacks the immune system, causing AIDS (Acquired 
Immune Deficiency Syndrome) if left untreated. Although not curable, infection can 
be well controlled by taking anti-retroviral medications. The success of anti-retroviral 
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treatment has reversed life expectancy from 48.0 years pre-ARVs to current life 
expectancy rates of 54.9 years in South Africa (Statistics South Africa, 2011) [3]. 
However, because ofthe decreased mortality due to ARVs the prevalence ofHIV is 
increasing and HIV continues to be one of the leading infectious diseases within sub-
Saharan Africa. 
4.2 Hepatitis B (HBV) 
It is estimated that two billion people worldwide have been infected with Hepatitis B 
(HBV) and more than 240 million people are living with chronic HBV [1]. An 
estimated 1.2 million people die annually from complications associated with chronic 
HBV [4]. Chronic HBV is endemic in many parts of Sub-Saharan Africa with 
prevalence rates varying from 0.3 to 15.0% [5]. HBV endemicity is defined as a 
population prevalence greater than 8% [6]. 
It has been estimated that carrier rates ofHBV range from 9.6% in South Africa to 
20.6% in the Democratic Republic of the Congo [7]. Even within South Africa, 
studies have shown marked differences in prevalence rates between rural and urban 
settings. Kew [8] reported a HBV prevalence rate of 15.5% from the Eastern Cape 
compared with 1.3% from Soweto. Black ethnic groups tend to have a higher HBV 
prevalence compared to other racial groups on the continent [9]. 
Hepatitis B can be a serious viral infection which affects the liver. The presence of 
HBsAg indicates HBV infection and the presence of HBsAg for a minimum of six 
months indicates chronic infection. There are two phases of illness an acute phase and 
chronic phase. The acute phase is characterized by loss of appetite, tiredness, 
diarrhoea, vomiting and jaundice. Acute hepatitis is often self-limiting and is usually 
followed by non-replicative infection phase [ 1 0]. In fact, more than 90% of adults 
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develop a broad immune response that eliminates replicating HBV DNA from blood 
and leads to protection against HBsAg [11]. Following acute infection, the risk of 
developing chronic infection varies inversely with age: 90% for perinatal infection, 
25-30% for infection at age 1-5 years and less than 10% for adults [12]. Patients who 
develop chronic HBV infection may often be asymptomatic but the infection can lead 
to liver cirrhosis, liver cancer and death, with an estimated 1 million people dying 
annually from HBV related disease [1]. Ma [13] estimates that HBV is the fourth 
most common cause of cancer death amongst Asian Americans. Approximately 20% 
of liver cirrhosis amongst black Africans is secondary to HBV [8]. 
The main mode of acquisition ofHBV in sub-Saharan Africa is horizontal 
transmission, with the majority of children between the age of six months and 5 years 
becoming infected through close contacts within households [14]. These children 
become chronic carriers of HBV and can transmit it in adulthood the same way as 
HIV [9]. 
Hepatitis B is a preventable disease. HBV vaccination has been routinely available as 
part ofthe Expanded Programme on Immunization (EPI) in South Africa since 1995, 
given at 6, 10 and 14 weeks of age [8] and has been rolled out in many other African 
countries between 1990 and 2001 [9]. Hepatitis B vaccine has a 95% efficacy rate and 
is the first vaccine against a major human cancer [1]. However, within South Africa, 
persons born before 1995 are susceptible to HBV. All HIV -infected persons should 
therefore be screened for HBV and vaccination provided if not immune or if they 
missed vaccination. 
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4.3 Co-infection 
Globally there is very little data on HIV /HBV co-infection rates, particularly in 
countries with a high prevalence of chronic hepatitis. It is estimated that 
approximately 10% of people living with HIV worldwide are also co-infected with 
HBV [15]. Studies from the developed world show that HBV infection is higher in 
HIV infected individuals compared to uninfected individuals [9]. A study conducted 
in an urban government clinic in South Africa showed that a HIV infected person was 
five times more likely to be infected with HBV compared to a HIV negative person 
[16]. Estimated co-infection rates in Sub-Saharan Africa are approximately 15.0% 
but can vary greatly between countries [17]. Co-infection prevalence rates in South 
Africa are currently unknown. Studies conducted in an urban clinic in Johannesburg 
estimated a 5.0% HBsAg positivity rates in HIV positive patients compared to 17.0% 
in an industrial clinic setting [ 16]. 
The South African HIV Clinicians Society [14] warns that HIV-HBV co-infected 
patients are at increased risk of morbidity and mortality. This may be due to increased 
HBV viral replication and hepatotoxicity induced by the combination of HBV and 
anti-retroviral medication [6]. There is also evidence to suggest that HIV accelerates 
the progress of HBV liver disease [17]. HIV positive patients with low CD4 counts 
are at increased risk for liver related mortality and reactivation of Hepatitis B in 
patients with developed immunity [18], [19]. Most of the literature suggests that HIV 
plays a role in HBV disease progression [1]. However, there is no evidence to suggest 
that HBV promotes HIV disease progression [20]. The World Health Organization's 
clinical protocol for Management ofHBV and HIV co-infection highlights that 
patients receiving anti-retroviral treatment have an increased risk of hepatotoxicity 
and that interruption in treatment can cause hepatic flare ups. 
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HIV -infected patients exposed to HBeAg have a reduced ability to develop non-
replicating HBV compared to HIV negative patients [21]. Reactivation can occur in 
immuno-compromised patients previously considered to have non-replicating 
infection [22]. 
Both the World Health Organization and the South African HIV Clinician's society 
recommend early screening for Hepatitis Bin HIV infected patients, ideally at the 
time of diagnosis. Despite these recommendations, the National Department of 
Health guidelines no longer recommend Hepatitis B testing in HIV infected adults. 
Hepatitis B screening (HBsAg) was advised in the 2010 guidelines in patients starting 
nevirapine but only in patients with a raised Alanine Transaminase (ALT) due to 
toxicity concerns of administering this drug in HBV infected patients. Prior to that, 
screening for HBsAg was not included in the guidelines. 
4.4 Co-infection treatment 
The ARVs lamivudine and tenofovir are part of the first line regimen for HIV. Both 
are also effective treatment ofHIV and HBV. Tenofovir was approved for the 
treatment of HBV in 2008 [ 17] and became available in South Africa in 2010. 
Lamivudine has a poor resistance profile and drug resistance mutations commonly 
occur after two to three years of use [23]. In addition HBV flare-ups often occur if 
lamivudine is stopped [24]. Tenofovir has a much better resistance profile and fewer 
side effects than lamivudine and is now part of first line therapy for HIV. Tenofovir 
can be used to treat both diseases and is often considered the preferred treatment in 
coinfected patients, because of this the National ART Guidelines no longer 
recommend screening for HBV. However, due to the lack of screening for HBV, 
patients are not diagnosed and their liver function tests are not being monitored. 
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There is no surveillance of HBV -related liver disease or adequate contact tracing to 
prevent the spread of HBV disease. 
HBV vaccination has been available in South Africa since 1995 [8] however there is 
still a cohort of patients who may have acquired HBV prior to the introduction of the 
vaccine and who are susceptible to HBV (including the majority of patients who 
participated in this study). 
The South African HIV Clinician's [14] society recommends: 
Screening for HBV on HIV diagnosis. 
CD4 to be taken on newly HIV diagnosed. 
AL T to be monitored on a six monthly basis. 
Vaccinating uninfected high risk individuals against Hepatitis B. 
Infants born to co-infected mothers should receive post exposure 
prophylaxis against HBV. 
Co-infected patients should be referred to a specialist. 
All co-infected individuals should be counselled on lifestyle modifications 
to reduce further liver damage- reduce alcohol intake, avoid herbal 
medications. 
4.5 Co-infection and abnormal liver function tests 
Liver function tests (LFTs) are a range of biochemical assays which indicate liver 
disease or damage, and elevated Aspartate Transaminase (AST) and ALT are specific 
biomarkers of liver damage. 
Monitoring of liver function tests in co-infected HIV /HBV is important as it gives an 
indication of liver damage. It is of particular relevance pre starting ARVs and once 
initiated on ARVs as it can give an indication of hepatic flare ups. 
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The normal range of liver function tests are outlined below: 
Table 1: Normal liver function ranges 
Blood Test Normal Range 
Bilirubin 0-21 ~mol/1 
Alkaline Phosphatase 40- 120 U/1 
y-Glutamyl Transferase (GGT) 0-35 U/1 
Alanine Transaminase (ALT) 5-40 U/1 
Aspartate Transaminase (AST) 5-40 U/1 
The World Health Organization recommends that liver function tests be monitored in 
HIV -infected patients on a regular basis- three to six monthly. There have been very few 
studies in South Africa to determine the effect of co-infection on liver function. A study 
conducted in the Chris Hani Baragwaneth hospital in Johannesburg showed that co-
infected patients had abnormal liver function tests. However, another study conducted in 
a South African urban clinic showed that liver function tests were not a good predictor of 
HBV infection [16]. 
5 Issues not addressed in the Literature 
The gaps in the literature have been divided into the following areas: 
5.1 Current co-infection prevalent HIVIHBV rates 
Although there are a number of studies on HIV and HBV, there are few studies on 
HIV /HBV co-infection in sub-Saharan Africa. There needs to be large scale 
prevalence studies on co-infection within sub-Saharan Africa. 
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5.2 Effective treatment of co-infection in sub-Saharan Africa 
There is limited data on ART treatment in co-infected patients. As both HIV and 
HBV are endemic in sub-Saharan Africa, this is an important area and warrants 
further studies. 
6 Need for further research 
Due to the limited data on HIV/HBV co-infection in sub-Saharan Africa and South 
Africa, health departments are not adequately prepared for the long term chronic 
effects of co-infection. As ARV programmes scale up across Africa, careful 
consideration needs to be given to the most appropriate treatment for co-infected 
individuals in places with endemic HBV rates. Currently there is no screening of 
patients for HBV prior to being placed on ART and thus there is very little data on 
whether patients are on the most appropriate ARV regimen given their co-infection 
status. 
7 Contribution of dissertation to literature 
This study will provide prevalence rates of HBV in a HIV infected population. This 
study will also investigate whether this cohort of patients are on appropriate anti-
retroviral treatment given their co-infection status. This study will also determine 
whether co-infection is associated with abnormal liver function. 
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Prevalence of Hepatitis B in HIV infected persons: Choice of antiretroviral 
therapy regimen and implications for screening. 
l. Abstract 
Background: Limited data and few studies have shown the prevalence of Hepatitis B in the 
HIV infected population in South Africa, whether these patients are on appropriate 
antiretroviral therapy and the effect of Hepatitis Bon liver function in co-infected persons. 
Objectives: The objectives ofthis study were to determine the prevalence of Hepatitis B 
surface antigemia (HBsAg) in healthy HIV positive persons screened for a vaccine trial and 
the proportion of those eligible for antiretroviral therapy that were receiving optimal anti-
viral treatment, namely tenofovir and/or lamivudine. The relationship between Hepatitis B 
carriage and liver function was also determined in co-infected persons as measured by liver 
function tests. 
Methods: A cross sectional study was conducted from 30th August 2011 to 24th April2013 to 
determine the prevalence ofHIV/HBV co-infection in persons attending a clinical trial site in 
an urban area of Cape Town. Participants self-presented to the clinic and once consented 
were enrolled into the study and provided blood for HIV confirmatory test, Hepatitis B s Ag, 
CD4, VL, full blood count, liver function and renal function tests. 
Results: 638 participants were enrolled into this cross sectional study (85.4% female, 70.8% 
on ARVs). The median age was 35 years (range 18-51) with a median CD4 count of 567 
106/1. (IQR 443-715). 24 (3.8%) were Hepatitis B sAg positive. Ofthe 24 HIV/HBV co-
infected participants, 19 (79.2%) were on antiretroviral therapy, 14 (73.7%) of these were on 
a tenofovir/lamivudine regimen the remaining 5 (26.3%) were not on a tenofovir regimen. 
Five ofthe co-infected participants were not on ARVs because their CD4 count was above 
the recommended South African guidelines for treatment i.e. greater than 350 I Q/'6/1. Male 
participants were three times more likely to be HBsAg positive (OR 3.11, 95% CI 1.29-7.49); 
and elevated Alanine aminotransferase (ALT) (OR 3.306 95% CI 1.32-8.26) and 
Aspartate Transaminase (AST) (OR 3.18, 95% CI 1.21- 8.34) were associated with HBsAg 
seropositivity. Age was not associated with the risk ofHBV co-infection. 
Conclusion: This study showed a lower HIV/HBV co-infection prevalence rate than reported 
from other locations in South Africa suggesting geographical variability. Appropriate 
guidelines are required to ensure that co-infected patients are identified and treated with the 
most appropriate anti-retroviral regimens. Also screening for HBV is recommended in HIV 
infected cohorts. 
Key words: HIV prevalence, Hepatitis B prevalence, HIV/Hepatitis B co-infection, 
Guidelines, Sub-Saharan Africa, South Africa. 
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2. INTRODUCTION 
HIV and Hepatitis B (HBV) represent two significant global health problems. Both are 
preventable viral infections with increasing prevalence. Currently there are an estimated 50 
million people living with HIV [1] and two billion people worldwide with Hepatitis B, with 
more than 240 million people living with chronic HBV [1]. Globally there is very little data 
on HIV /HBV co-infection. Studies from the developed world show that HBV infection is 
higher in HIV infected individuals compared to uninfected individuals [2]. Estimated co-
infection rates in Sub-Saharan Africa are approximately 15.0% but can vary greatly between 
countries [3]. Co-infection prevalence rates in South Africa are currently unknown. Studies 
conducted in an urban clinic in Johannesburg estimated a 5.0% HBsAg positivity rate in HIV 
positive patients compared to 17.0% in an industrial clinic setting [4]. South Africa has one 
of the highest HIV prevalence rates in the world, with an estimated 10.6% of the population 
infected with HIV in 2011 [5]. There has been a strong drive within the last few years to 
increase screening rates for HIV and to provide HIV positive people with appropriate medical 
care, however HBV screening is not conducted in South Africa and the current co-infected 
prevalence rates are unknown. 
The current standard of care against HBV is vaccination at birth which has been implemented 
since 1995 [6]. People who test HIV positive are monitored routinely and initiated on ARVs 
once their CD4 count is below 350 x 101'6/L. Tenofovir has been part of the first line 
treatment for HIV in South Africa since 2010 and lamivudine since 2004, both ofthese drugs 
are effective in the management ofHBV. Lamivudine has a poor resistance profile and drug 
resistance mutations commonly occur after two to three years of use [7]. In addition HBV 
flare-ups often occur if lamivudine is stopped [7]. Tenofovir has a much better resistance 
profile and fewer side effects than lamivudine. Tenofovir can be used to treat both diseases 
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and because of this the National ART Guidelines no longer recommend screening for HBV. 
Many co-infected patients initiated on ART prior to 2010 may not be on tenofovir. 
Currently the Southern African HIV Clinicians Society recommends screening for HBV on 
initial diagnosis ofHIV. However, in the 2010 Department ofHealth HIV management 
guidelines, stavudine has been replaced with tenofovir and screening for HBV is no longer 
required. The proportion of co-infected positive persons on appropriate antiretroviral 
treatment is not known. The purpose of this study is to evaluate the prevalence ofHIV/HBV 
co-infection and the number of persons on appropriate anti-retroviral treatment. 
3. METHODS 
3.1 Setting and population 
This study was part of a TB vaccine trial conducted in an urban clinic in Khayelitsha, Cape 
Town. Participants were recruited from surrounding township clinics and self-presented to 
the clinic for enrolment into the study. Radio and newspaper adverts were also used as a 
recruitment tool. 
Participants were recruited from 301h August 2011 to 241h April2013. As part of the TB 
vaccine trial, participants signed a full informed consent, had a complete TB screen 
conducted and bloods taken for confirmation of HIV status, Hepatitis B screening, CD4, HIV 
viral load and liver profile. 
Participants were HIV -infected males and females aged 18 to 51 years old, who had no 
current signs or symptoms of tuberculosis at the initial assessment, their most recent CD4 
result was greater than 3 00 x 1 W'6/L if on ARV s and if AR V naive greater than 3 50 
x 1 Q!'6/L. Pregnant women were excluded. A total of six hundred and ninety six participants 
consented for the TB vaccine trial; six hundred and thirty eight participants had bloods taken 
and were included in this cross sectional prevalence study. 
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Khayelitsha is an urban township in Cape Town comprising of formal and informal housing. 
Adults aged 15-54 years of age comprise of 66.7 % of the population. Half of all adults are 
unemployed and of those employed, 80% earn less than R1600 per month [8]. 
Figure 1: Cape Town with Khayelitsha 
i. 
J 
\ 
[9] 
3.2 Study design and collection 
All data was collected by the TB vaccine trial. Trained research field workers and 
professional nurses obtained the demographic information and professional nurses collected 
blood samples. 
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3.3 Data analysis 
All data were double entered in EXCEL and then cross referenced to ensure consistency. 
Stata version 12 (Stata Corp. LP, College Station, TX, United States of America) was used 
for all analyses. Descriptive statistics were conducted calculating means, standard deviations 
for normally distributed data and mean and interquartile ranges used for data not normally 
distributed. Odds ratios were used to identify measures of association between HBV status 
and variables such as sex. Logistic regression was used to explore factors associated with 
HBV/HIV co-infection. Significantly associated risk factors that were identified were then 
introduced into a respective multivariable model with variables being retained in the final 
model if associated likelihood ratio test showed a P value of <0.05. 
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4. Ethical Considerations 
All participants signed informed consent prior to participating in the vaccine trial (REC 
REF: 001/2010). This study was granted full ethics approval by the University of Cape Town 
Human Research Ethics Committee (HREC REF: 305/2013). 
5. RESULTS 
5.1 Demographic Data 
A total of 638 participants were included in this cross sectional study and the majority were 
female (n=545, 85.4 %,).The median age was 34.6 years (range 18-51). 
31% (n= 197) of participants lived in a house or formal building, 33.4% (n=213) lived in 
informal dwellings with sanitation and the remainder 35.7% (n=228) lived in informal 
dwelling without sanitation but had access to a communal toilet. 
The overall prevalence rate ofHBV was 3.8% (n=24). Over seventy percent (n=447) of all 
participants were on anti-retrovirals. The majority of women (78.3 % n= 426) described 
themselves as non-drinkers whereas more than half of the men (52. 7% n=49) consumed 
alcohol. 
There was a higher proportion of men co-infected (8.6% n=8) compared to women (2.9% 
n=16). 
Table 1 presents the demographic information and HBV, ARV status categorized by gender. 
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Table 1: Demographic data, HBV and ARV status of participants in study 
%Total 
On ARVs 
Not on 
ARVs 
Drinker 
Non 
Drinker 
e of accommodation 
sanitation 
Informal 
building 
with 
communal 190 
37.4; SD 34.6; SD 
48 
<0.001 
0.544, 0.864 
95% Cl of 
the 
difference 
-4.76 to -
1.78 
0.539, 
1.386 
0.015f, 3.112 1.292, 
<0.001, 0.308 
7.495 
0.196, 
0.486 
0.325 N/ A N/ A 
5.2 CD4 counts and Viral Loads 
The median CD4 count ofthe cohort was 567 x 10/\6/1 (IQR 447-716 x 10/\6/1). Overall, 
70.4% of the cohort (n=447) were on anti-retrovirals ofwhom 23.3% (n=55) had a detectable 
viral load. 
5.3 Co-infection and ARVs 
24 participants were co-infected, 5 of whom were ARV naive as their CD4 count did not 
meet the eligibility criteria for initiating therapy according to the South African guidelines. 
The remaining 19 participants (79.1%) were on ARVs ofwhom 14 (73.7%) were on a 
tenofovir/lamivudine based regimen, and 5 (26.3%) were on a lamivudine containing regimen 
without tenofovir. 
5.4 Liver function test 
Table 2 presents the features of the co-infected participants and those who were not Hepatitis 
B infected within the cohort. A greater proportion of men than women were co-infected, men 
were three times more likely to be HBsAg positive. 9.3% (n=7) of the HIV/HBV co-infected 
cohort had abnormal ALTs and 9.4% (n=6) of co-infected participants had abnormal AST 
results. 
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T bl 2 H ff B I 
Hep B sAg Hep BAg Odds 
negative positive P value, Ratio Cl of OR 
Variable (N=614) (N=24) Total unadjusted 
93 3.112 1.292, 7.495 
Males 85 (91.4%) 8 (8.6%) (100.0%) 
545 
Females 529 (97.1%) 16 (2.9%) (100.0%) 0.015f, 
Age mean (SD) 34.54 (6.64) 36.25(6.76) 0.231 -1.09 to 4.50 
447 1.625 0.598, 4.418 
On ARVs 428 (95.7%) 19 (4.3%) (100%) 
188 0.921, 
Not on ARVs 183 (97.3%) 5 (2.7%) (100.0%) 
162 1.308 0.481, 3.562 
Drinker 157 (96.9%) 5 (3.1%) (100%) 
476 0.598, 
Non-drinker 456 (96.0%) 19 (4.0%) (100%) 
ALT abnormal (if 75 3.306 1.323, 8.260 
>40 U/1) 68 (90.7%) 7 (9 .3%) (100%) 
ALT normal (if 563 
<=40 U/1) 546 (97.0%) 17 (3.0%) (100%) 0.016f, 
AST abnormal (if 64 3.184 1.216, 8.338 
> 40 U/1) 58 (90.6%) 6 (9.4%) (100%) 
AST normal (if<= 572 
40 U/1) 554 (96.9%) 18 (3.1%) (100%) 0.026f, 
AP abnormal (if 67 1.223 0.355, 4.215 
>120 U/1) 64 (95.5%) 3 (4.5%) (100%) 
AP normal (if 569 
<=120 U/1) 548 (96.3%) 21 (3 .7%) (100%) 0.732f, 
GGT abnormal (if 318 2.060 0.869, 4.883 
>35 U/1) 302 (95.0%) 16(5%) (100%) 
GGT normal (if 319 
<=35 U/1) 311 (97.5%) 8 (2.5%) (100%) 0.094, 
Bilirubin 8.855 0.887, 88.423 
abnormal (if> 21 4 
llmol/1) 3 (75%) 1 (25%) (100%) 
Bilirubin normal 634 
(if<= 211lmol/l) 611 (96.4%) 23 (3 .6%) (100%) 0.143f, 
Platelets 0.394 0.052, 2.970 
abnormal (if> 62 
400 X 10"9/1) 61 (98.4) 1 (1.6%) (100%) 
Platelets normal 
(if<= 400 X 576 
10"9/1) 553 (96.0%) 23 (4.0%) (100%) 0.499f, 
For those on ARVs 44 4.591 1.650, 12.773 
VL abnormal >40 38 (86.4%) 6 (13.6%) (100%) 
For those on ARVs 
VL normal <=40 391 
orLDL 378 (96.7%) 13 (3 .3%) (100%) 0.008f, 
f = fisher 's exact test 
so 
5.5 Impact of co-infection on liver function 
Co-infected participants were 3.3 times more likely to have abnormal AL T results and 3.5 
times more likely to have abnormal AST results in this prevalence study. These results were 
statistically significant. 
T bl 3 I • t f t f bl d 
p Confidence Adjusted 
Variables value Interval OR 
ALT 0.010 1.323, 8.260 3.337 
AST 0.018 1.216, 8.338 3.486 
AP 0.750 0.355, 4.215 1.050 
GGT 0.101 0.869, 4.883 1.911 
Bilirubin 0.063 0.887, 88.423 10.761 
Platelets 0.366 0.052, 2.970 0.390 
*adjusted for age/gender/ARVs/Aicohol 
6. Discussion 
This study of 638 healthy HIV -infected participants from Khayelitsha included a high 
proportion of women reflecting the predominance of women attending HIV services in the 
public sector and volunteering for studies. South African women have had an earlier exposure 
to HIV services through MTCT prevention programs and many cohorts reflect this gender 
imbalance [10]. The overall prevalence of3.8% HBV/HIV co-infection rates in our study was 
lower than expected when compared to other studies [ 4]. Previous prevalence studies on 
HBV mono-infection conducted in South Africa, reveal varying results from 1 %in urban 
areas to up to 10% in rural areas [4] ; [2]. Two different studies conducted in Johannesburg 
HIV clinics with a similar median age to this study showed a 5% prevalence of co-infection 
in a government ARV clinic [11], [4]. HIV programs in an industrial mining setting revealed 
20% of their total cohort (predominantly men) were co-infected [12]. The lower prevalence 
rate in our study may be due to the fact that this population were healthier and had higher 
CD4 counts compared to previous studies [13]. It may also be due to the low proportion of 
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men aware of their HIV status and attending services and recruited into this study, as men 
have a higher prevalence ofHBsAg carriage compared to women [6]. The low prevalence of 
co-infection was surprising as a large proportion of residents ofKhayelitsha have recently 
migrated from the Eastern Cape [14] and studies show that the prevalence of Hepatitis B is 
much higher in communities in the Eastern Cape [ 6]. 
This study revealed that co-infected participants were 3.3 times more likely to have some 
degree of liver inflammation as indicated by an abnormal AL T and AST results compared to 
mono HIV infected participants. However, other studies have produced conflicting reports 
regarding impaired liver function tests and co-infection. AL T levels tend to be lower or 
within normal ranges within co-infected patients [ 11] however, significant fibrosis can still be 
present [15]. 
Further studies have shown elevated liver function tests in the majority of AIDS patients who 
were co-infected [16],[13]. In contrast, one ofthe studies conducted in Johannesburg showed 
that liver function tests were not an adequate marker ofHBV infection as ALT results were 
often normal in co-infected patients [4]. 
Our study shows a correlation between raised AL T and AST and co-infection, however this 
result should be viewed with caution as the majority of these patients were on ARV s. AL T 
levels can fluctuate in co-infected patients for many reasons such as effects of antiretrovirals, 
alcohol consumption and immune reconstitution [ 15]. Also intermittent AL T elevations can 
be seen during hepatic flare ups [15]. Raised HBV DNA levels are a more accurate measure 
ofliver damage [15] but this test was not conducted as part ofthis study. 
Of the 24 HIV /HBV co-infected participants, 19 (79 .2%) were on antiretroviral therapy, 14 
(73.7%) ofthese were on a tenofovir/lamivudine regimen and the remaining 5 (26.3%) were 
not on the recommended tenofovir regimen. The inappropriate ARV choice may be a result 
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of lack of screening for HBV. Five ofthe co-infected participants were not on ARVs because 
their CD4 count was above the recommended South African guidelines for treatment i.e. 
greater than 350 x lQ/'6/l. Although, the numbers ofHBV positive individuals in this study 
are small, it indicates the need for HBV screening in all HIV diagnosed patients and to ensure 
that co-infected patients are on appropriate treatment. Appropriate medical follow-up for co-
infected patients is also necessary. However, this has not been included in the national 
guidelines although recommended by the South African Clinician's Society. 
Possible limitations to this study were low recruitment numbers for the sub analysis of the co-
infected group and a disproportionate low number of males recruited into the study which 
could account for the low prevalence rates. Also, this cohort of patients were healthy HIV 
infected adults with high CD4 counts and were proactively engaged in their health care 
management. Limited Hepatitis B testing was conducted; HBsAg was the only test 
conducted, other markers such as Hepatitis B e Ag or HBV DNA were not conducted which 
can give a better indication ofliver damage in co-infected patients. Overall, the estimate for 
the proportion of co-infected persons in our sample was 24 (95% CI 1.3 to 7.5) and therefore 
we cannot generalise to other populations with accuracy. 
7. Conclusion 
Screening for HBV is recommended by both the World Health Organization and the South 
African HIV Clinician's Society. This is not being routinely conducted in South Africa. 
Given the varying co-infection estimation rates throughout the country routine HBV 
screening is required to accurately estimate rates of co-infection. However this would have 
cost and logistical implications which may be impractical given the current demand on the 
South African healthcare system. A more practical recommendation may be to initiate HBV 
screening in patients with raised LFTs 
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The rate of HIV /Hep B co-infection was lower than expected within this cohort but this may 
have been due to the predominance of women and the fact that participants in a trial were 
more likely to be healthy with higher median CD4 counts. Despite improvements in ARV 
treatment guidelines and the introduction of tenofovir as first line treatment, this study 
revealed that co-infected participants are on inappropriate ARVs. This warrants further 
investigation. 
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Apendix 1: Inclusion/Exclusion Criteria to TB Vaccine Trial 
Inclusion Criteria 
Subjects must meet all of the following criteria at the time of randomization: 
1. Has completed the written informed consent process prior to undergoing any 
screening evaluations. 
2. Either males or females aged 2::18 and ~50 years on Study Day 0 
3. In general good health, confirmed by medical history and physical examination 
4. Has ability to complete follow-up period as required by the protocol 
5. Has laboratory evidence of human immunodeficiency virus (HIV) infection, defined 
as a positive HIV -1 ELISA test plus a positive confirmatory test (e.g., a second HIV -1 
ELISA, PCR, or rapid ELISA) diagnosed prior to randomization 
6. Is willing to allow the investigators to discuss the subject's medical history with the 
subject's HIV physician 
7. If not receiving ART at the time of randomization, must have 2 CD4+ lymphocyte 
count test results >350 cells/mm3, performed at least 4 weeks apart, one performed 
within 6 months prior to randomization and one within 45 days prior to randomization 
8. If receiving antiretroviral therapies (ART) at the time of randomization, must have 2 
CD4+ lymphocyte count test results > 300 cells/mm3, performed at least 4 weeks 
apart, one performed within 6 months prior to randomization and one within 45 days 
prior to randomization 
a. Subjects on ART must have been receiving ART for at least 6 months prior to 
randomization and must have an undetectable HIV viral load within 45 days 
prior to randomization 
b. Women who received ART as part of the PMTCT program must have 
completed therapy at least 2 months prior to randomization 
9. Has either 
a. a negative QuantiFERON-TB Gold In-Tube test result and tuberculin PPD 
skin test ::S5 mm induration within 45 days prior to randomization or 
b. a positive QuantiFERON-TB Gold In-Tube test result and/or tuberculin PPD 
skin test >5 mm and has completed at least 5 months of isoniazid preventive 
therapy within 3 years prior to randomization or 
c. a positive QuantiFERON-TB Gold In-Tube test result and/or tuberculin PPD 
skin test >5 mm and has completed treatment for TB disease within 3 years 
prior to randomization 
10. Females: Ability to avoid pregnancy during the trial. Women physically capable of 
pregnancy (not sterilized and still menstruating or within 1 year of the last menses if 
menopausal) in sexual relationships with men must avoid pregnancy by using an 
acceptable method of avoiding pregnancy from 28 days prior to administration of the 
study vaccine through 6 months after the last study vaccination. Acceptable methods 
of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not 
engaging in sexual intercourse), and any contraceptive method deemed clinically 
suitable by the trial clinician taking into account ART status. 
11. Has completed the written informed consent process for simultaneous enrollment in 
Aeras Vaccine Development Registry protocol 
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